AML Authorized Value Terminology

Preferred Label : AML Authorized Value Terminology;

NCIt synonyms : Acute Myeloid Leukemia Authorized Value Terminology;

NCIt definition : Terms that have been designated as being a authorized value within the PCDC Terminology and AML project.;

NCI Metathesaurus CUI : CL1407922;

Details

Origin ID

C174019;

UMLS CUI

C5783392;

Semantic type(s)
- Intellectual Product [UMLS semantic type]
concept_is_in_subset
- PCDC Terminology [NCIt concept]
subset_includes_concept
- AAML03P1 AML Study Identifier [NCIt concept]
- AAML0531 AML Study Identifier [NCIt concept]
- AAML1031 AML Study Identifier [NCIt concept]
- ACE Inhibitor [NCIt concept]
- AEIOPLAM2002 AML Study Identifier [NCIt concept]
- AIEOPLAM92 AML Study Identifier [NCIt concept]
- AMLBFM1998 AML Study Identifier [NCIt concept]
- AMLBFM2004 AML Study Identifier [NCIt concept]
- AMLBFM2012 AML Study Identifier [NCIt concept]
- AMLBFMRegistry2012 AML Study Identifier [NCIt concept]
- AMLBFMRegistry2017 AML Study Identifier [NCIt concept]
- Acute Basophilic Leukemia [NCIt concept]
- Acute Erythroid Leukemia [NCIt concept]
- Acute Graft Versus Host Disease [NCIt concept]
- Acute Megakaryoblastic Leukemia [NCIt concept]
- Acute Monoblastic and Monocytic Leukemia [NCIt concept]
- Acute Myeloid Leukemia (Megakaryoblastic) with t(1;22)(p13.3;q13.1); RBM15-MKL1 [NCIt concept]
- Acute Myeloid Leukemia with BCR-ABL1 [NCIt concept]
- Acute Myeloid Leukemia with Biallelic CEBPA Mutation [NCIt concept]
- Acute Myeloid Leukemia with Maturation [NCIt concept]
- Acute Myeloid Leukemia with Minimal Differentiation [NCIt concept]
- Acute Myeloid Leukemia with NPM1 Mutation [NCIt concept]
- Acute Myeloid Leukemia with RUNX1 Mutation [NCIt concept]
- Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 [NCIt concept]
- Acute Myeloid Leukemia with inv(3)(q21.3;q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM [NCIt concept]
- Acute Myeloid Leukemia with t(6;9)(p22.3;q34.1); DEK-NUP214 [NCIt concept]
- Acute Myeloid Leukemia with t(8;21)(q22; q22.1); RUNX1-RUNX1T1 [NCIt concept]
- Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A [NCIt concept]
- Acute Myeloid Leukemia without Maturation [NCIt concept]
- Acute Myeloid Leukemia, Myelodysplasia-Related [NCIt concept]
- Acute Myeloid Leukemia, Not Otherwise Specified [NCIt concept]
- Acute Myelomonocytic Leukemia [NCIt concept]
- Acute Myelomonocytic Leukemia with Abnormal Eosinophils [NCIt concept]
- Acute Panmyelosis with Myelofibrosis [NCIt concept]
- Acute Promyelocytic Leukemia [NCIt concept]
- Adverse Event [NCIt concept]
- Adverse Event Contributory to Cause of Death [NCIt concept]
- Adverse Event Definitely Related to Intervention [NCIt concept]
- Adverse Event Possibly Related to Intervention [NCIt concept]
- Adverse Event Probably Related to Intervention [NCIt concept]
- Adverse Event Unlikely Related to Intervention [NCIt concept]
- Adverse Event Unrelated to Intervention [NCIt concept]
- Alive [NCIt concept]
- Allogeneic Hematopoietic Stem Cell Transplantation [NCIt concept]
- American Indian or Alaska Native [NCIt concept]
- Amsacrine [NCIt concept]
- Arsenic Trioxide [NCIt concept]
- Asian [NCIt concept]
- Auer Rod Measurement [NCIt concept]
- Autologous Hematopoietic Stem Cell Transplantation [NCIt concept]
- Bacteria [NCIt concept]
- Bacterial Infection [NCIt concept]
- Berlin-Frankfurt-Munster Study Group [NCIt concept]
- Biallelic CEBPA Gene Mutation [NCIt concept]
- Biological Parent [NCIt concept]
- Biological Relative [NCIt concept]
- Biological Sibling [NCIt concept]
- Biologically Unrelated [NCIt concept]
- Black or African American [NCIt concept]
- Blast Count [NCIt concept]
- Blood Sample [NCIt concept]
- Body Height [NCIt concept]
- Body Mass Index [NCIt concept]
- Body Weight [NCIt concept]
- Bone [NCIt concept]
- Bone Marrow [NCIt concept]
- Bone Marrow Analysis [NCIt concept]
- Bone Marrow Response [NCIt concept]
- Bone Marrow Sample [NCIt concept]
- Bone Marrow Test Result [NCIt concept]
- Bortezomib [NCIt concept]
- Busulfan [NCIt concept]
- CEBPA Gene Mutation [NCIt concept]
- CNS 1 [NCIt concept]
- CNS 2 [NCIt concept]
- CNS 3 [NCIt concept]
- CNS Response [NCIt concept]
- CSF Analysis [NCIt concept]
- CSF Results [NCIt concept]
- Capillary Electrophoresis [NCIt concept]
- Centimeter [NCIt concept]
- Central Nervous System [NCIt concept]
- Cerebrospinal Fluid Sample [NCIt concept]
- Chemotherapy [NCIt concept]
- Childhood Acute Promyelocytic Leukemia with t(15;17)(q24.1;q21.2); PML-RARA [NCIt concept]
- Children's Oncology Group [NCIt concept]
- Chimeric Antigen Receptor T-Cell Therapy [NCIt concept]
- Chromosomal Rearrangement [NCIt concept]
- Chromosomal Translocation [NCIt concept]
- Chronic Graft Versus Host Disease [NCIt concept]
- Cladribine [NCIt concept]
- Clofarabine [NCIt concept]
- Common Terminology Criteria for Adverse Events [NCIt concept]
- Complete Remission [NCIt concept]
- Confirmation [NCIt concept]
- Consent Withdrawn [NCIt concept]
- Consolidation Therapy [NCIt concept]
- Copy Number Polymorphism [NCIt concept]
- Count per Cubic Millimeter [NCIt concept]
- Cyclophosphamide [NCIt concept]
- Cytarabine [NCIt concept]
- DBAML01 AML Study Identifier [NCIt concept]
- Daunorubicin [NCIt concept]
- Dead [NCIt concept]
- Death Indicator [NCIt concept]
- Death Related to Adverse Event [NCIt concept]
- Death due to Disease Progression [NCIt concept]
- Death, Adverse Event is Noncontributory [NCIt concept]
- Deletion Mutation [NCIt concept]
- Dexrazoxane [NCIt concept]
- Donor Lymphocyte Infusion [NCIt concept]
- Doxorubicin [NCIt concept]
- Dutch Childhood Oncology Group [NCIt concept]
- Echocardiogram Recording [NCIt concept]
- End of Planned Treatment [NCIt concept]
- Erythrocyte Count [NCIt concept]
- Etoposide [NCIt concept]
- European Society for Blood and Marrow Transplantation [NCIt concept]
- Exchange Transfusion [NCIt concept]
- FLT3 Internal Tandem Duplication [NCIt concept]
- FLT3 Tyrosine Kinase Domain Point Mutation [NCIt concept]
- Female [NCIt concept]
- Flow Cytometry [NCIt concept]
- Flow Cytometry Different from Normal [NCIt concept]
- Flow Cytometry for Leukemia-Associated Immunophenotypes [NCIt concept]
- Fludarabine [NCIt concept]
- Fluorescence In Situ Hybridization [NCIt concept]
- Fungal Infection [NCIt concept]
- Fungus [NCIt concept]
- GATA1 Gene Mutation [NCIt concept]
- Gastrointestinal Tract [NCIt concept]
- Gel Electrophoresis [NCIt concept]
- Gemtuzumab Ozogamicin [NCIt concept]
- Gilteritinib [NCIt concept]
- Graft Versus Host Disease [NCIt concept]
- Gram per Deciliter [NCIt concept]
- Gray [NCIt concept]
- HLA Match [NCIt concept]
- HLA Mismatch [NCIt concept]
- Heart Failure [NCIt concept]
- Heart Transplantation [NCIt concept]
- Hematologic Neoplasm Associated with Down Syndrome [NCIt concept]
- Hematopoietic Cell Transplantation [NCIt concept]
- Hematopoietic Cell Transplantation Conditioning Regimen [NCIt concept]
- Hemoglobin Measurement [NCIt concept]
- Hemorrhage [NCIt concept]
- Hispanic or Latino [NCIt concept]
- Hydrocortisone Sodium Succinate [NCIt concept]
- Hyperbilirubinemia [NCIt concept]
- Idarubicin [NCIt concept]
- Imaging Procedure [NCIt concept]
- Immunotherapy [NCIt concept]
- Induction Therapy [NCIt concept]
- Infection [NCIt concept]
- Initial Diagnosis [NCIt concept]
- Inotropic Support [NCIt concept]
- Intensification Therapy [NCIt concept]
- Intrathecal Space [NCIt concept]
- Inversion Mutation Abnormality [NCIt concept]
- Italian Association of Pediatric Hematology and Oncology [NCIt concept]
- JACLSAML99 AML Study Identifier [NCIt concept]
- JPLSGAML05 AML Study Identifier [NCIt concept]
- Japan Association of Childhood Leukemia Study [NCIt concept]
- Japanese Pediatric Leukemia/Lymphoma Study Group [NCIt concept]
- KIT Exon 17 Mutation [NCIt concept]
- KIT Exon 8 Mutation [NCIt concept]
- KIT Gene Mutation [NCIt concept]
- KMT2A Gene Rearrangement [NCIt concept]
- KRAS Gene Mutation [NCIt concept]
- Karyotyping [NCIt concept]
- Kilogram [NCIt concept]
- Kilogram per Square Meter [NCIt concept]
- Left Ventricular Ejection Fraction [NCIt concept]
- Left Ventricular Fractional Shortening [NCIt concept]
- Left Ventricular Systolic Dysfunction [NCIt concept]
- Leukocyte Count [NCIt concept]
- Life Threatening or Disabling Adverse Event [NCIt concept]
- Liposomal Daunorubicin Citrate [NCIt concept]
- Liposome-encapsulated Daunorubicin-Cytarabine [NCIt concept]
- Liver [NCIt concept]
- Loss of Chromosome 17p [NCIt concept]
- Lung [NCIt concept]
- MRCAML12 AML Study Identifier [NCIt concept]
- MRCAML15 AML Study Identifier [NCIt concept]
- Maintenance Therapy [NCIt concept]
- Male [NCIt concept]
- Match at Both HLA Alleles [NCIt concept]
- Medical Research Council [NCIt concept]
- Medication Administered [NCIt concept]
- Medication Not Administered [NCIt concept]
- Melphalan [NCIt concept]
- Methotrexate [NCIt concept]
- Microgram per Milliliter [NCIt concept]
- Microgranular Acute Promyelocytic Leukemia [NCIt concept]
- Midostaurin [NCIt concept]
- Mild Adverse Event [NCIt concept]
- Milligram per Square Meter [NCIt concept]
- Millimeter per Hour [NCIt concept]
- Mismatch at Both HLA Alleles [NCIt concept]
- Mismatch at One HLA Allele [NCIt concept]
- Mitoxantrone [NCIt concept]
- Moderate Adverse Event [NCIt concept]
- Monoallelic CEBPA Gene Mutation [NCIt concept]
- Monosomy 5 [NCIt concept]
- Monosomy 7 [NCIt concept]
- Morphologic Finding [NCIt concept]
- Multiple Organ Failure [NCIt concept]
- Multiracial [NCIt concept]
- Mutation Abnormality [NCIt concept]
- Myeloablative Conditioning [NCIt concept]
- Myeloid Leukemia Associated with Down Syndrome [NCIt concept]
- Myeloid Neoplasm Post Cytotoxic Therapy [NCIt concept]
- Myeloid Sarcoma [NCIt concept]
- Myeloid Sarcoma Response [NCIt concept]
- NOPHOAML2004 AML Study Identifier [NCIt concept]
- NOPHOAML2012 AML Study Identifier [NCIt concept]
- NPM1 Gene Mutation [NCIt concept]
- NRAS Gene Mutation [NCIt concept]
- Native Hawaiian or Other Pacific Islander [NCIt concept]
- Negative Finding [NCIt concept]
- Neurotoxicity Syndrome [NCIt concept]
- Next Generation Sequencing [NCIt concept]
- Non-KMT2A MLLT10 Rearrangement Positive [NCIt concept]
- Non-response per Protocol [NCIt concept]
- Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation [NCIt concept]
- Nordic Society of Pediatric Haematology and Oncology [NCIt concept]
- Not Done [NCIt concept]
- Not Hispanic or Latino [NCIt concept]
- Not Recovered from Adverse Event [NCIt concept]
- Not Reported [NCIt concept]
- Off Protocol Therapy [NCIt concept]
- Off Study [NCIt concept]
- Orbit [NCIt concept]
- Other [NCIt concept]
- Overall Response [NCIt concept]
- PPLLSGAML98 AML Study Identifier [NCIt concept]
- PTPN11 Gene Mutation [NCIt concept]
- Palliative Therapy [NCIt concept]
- Percent Unit [NCIt concept]
- Peripheral Blood [NCIt concept]
- Peripheral Blood Analysis [NCIt concept]
- Physician Decision [NCIt concept]
- Platelet Count [NCIt concept]
- Platelets Product [NCIt concept]
- Polish Pediatric Leukemia/Lymphoma Study Group [NCIt concept]
- Positive Finding [NCIt concept]
- Post-treatment Disease Complication [NCIt concept]
- Pre-treatment Disease Complication [NCIt concept]
- Prephase Chemotherapy Treatment [NCIt concept]
- Primary Cause of Death [NCIt concept]
- Progressive Disease [NCIt concept]
- Pure Erythroid Leukemia [NCIt concept]
- Quizartinib [NCIt concept]
- RUNX1 Gene Mutation [NCIt concept]
- Real Time PCR [NCIt concept]
- Recovered from Adverse Event [NCIt concept]
- Recovered from Adverse Event with Sequelae [NCIt concept]
- Recurrent Disease [NCIt concept]
- Red Blood Cells Product [NCIt concept]
- Reduced-Intensity Transplant Conditioning Procedure [NCIt concept]
- Reverse Transcriptase-Polymerase Chain Reaction [NCIt concept]
- SCFEELAM02 AML Study Identifier [NCIt concept]
- SJCRHAML02 AML Study Identifier [NCIt concept]
- Secondary Malignant Neoplasm [NCIt concept]
- Severe Adverse Event [NCIt concept]
- Sign or Symptom [NCIt concept]
- Simple Transfusion [NCIt concept]
- Single Nucleotide Variant [NCIt concept]
- Sinusoidal Obstruction Syndrome [NCIt concept]
- Skin [NCIt concept]
- Skull [NCIt concept]
- Sorafenib [NCIt concept]
- Source Leukocytes [NCIt concept]
- St. Jude Children's Research Hospital [NCIt concept]
- Stem Cell Mixture [NCIt concept]
- Study Subject Enrolled [NCIt concept]
- Study Subject Not Enrolled [NCIt concept]
- Subject Lost to Follow Up [NCIt concept]
- Subject/Guardian Refused Further Treatment [NCIt concept]
- Suspected [NCIt concept]
- Systemic [NCIt concept]
- Testis [NCIt concept]
- Therapeutic Apheresis [NCIt concept]
- Thiotepa [NCIt concept]
- Transient Abnormal Myelopoiesis Associated with Down Syndrome [NCIt concept]
- Treatment-Related Mortality [NCIt concept]
- Tretinoin [NCIt concept]
- Trisomy 21 [NCIt concept]
- Trisomy 21 Mosaicism [NCIt concept]
- Trisomy 8 [NCIt concept]
- Typhlitis [NCIt concept]
- Umbilical Cord Blood [NCIt concept]
- Unit per Liter [NCIt concept]
- Unknown [NCIt concept]
- Viral Infection [NCIt concept]
- Virus [NCIt concept]
- WT1 Gene Mutation [NCIt concept]
- White [NCIt concept]
- Yes [NCIt concept]
- del(13q14-q21) [NCIt concept]
- del(5q31-q32) [NCIt concept]
- der12p [NCIt concept]
- inv(16)(p13.1;q22) [NCIt concept]
- inv(16)(p13.3;q24.3) [NCIt concept]
- inv(3)(q21.3;q26.2) [NCIt concept]
- t(10;11)(p11.2;q23) [NCIt concept]
- t(10;11)(p12;q23) [NCIt concept]
- t(11;15)(p15;q35) [NCIt concept]
- t(11;17) [NCIt concept]
- t(11;19)(q23.3;p13.1) [NCIt concept]
- t(11;19)(q23.3;p13.3) [NCIt concept]
- t(11;19)(q23;p13) [NCIt concept]
- t(15;17)(q24;q21) [NCIt concept]
- t(16;16)(p13.1;q22) [NCIt concept]
- t(16;21)(p11;q22) [NCIt concept]
- t(16;21)(q24;q22) [NCIt concept]
- t(1;11)(q21;q23) [NCIt concept]
- t(1;22) [NCIt concept]
- t(2;12) [NCIt concept]
- t(3;12)(q23;p12.3) [NCIt concept]
- t(3;3)(q21.3;q26.2) [NCIt concept]
- t(3;5)(q25;q34) [NCIt concept]
- t(4;11)(q21;q23.3) [NCIt concept]
- t(5;11)(q35;p15) [NCIt concept]
- t(6;11)(q27;q23) [NCIt concept]
- t(6;9)(p22.3;q34.1) [NCIt concept]
- t(7;12)(q36;p13) [NCIt concept]
- t(8;16) [NCIt concept]
- t(9;11)(p21.3;q23.3) [NCIt concept]
- t(9;22)(q34.1;q11.2) [NCIt concept]
- t(v;11q23.3) [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients